FDA Reevaluates CMC Regulations, Seeks Greater Flexibility
Executive Summary
FDA is reevaluating its chemistry, manufacturing & controls draft guidance to seek greater flexibility for drug manufacturers in meeting CMC regulation, Office of Pharmaceutical Science Director Helen Winkle said March 1